Bjerager Jakob, Hajari Javad, Klefter Oliver Niels, Subhi Yousif, Schneider Miklos
Department of Ophthalmology, Rigshospitalet Glostrup, Valdemar Hansens Vej 1-23, 2600, Glostrup, Denmark.
Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark.
Int Ophthalmol. 2024 Feb 8;44(1):37. doi: 10.1007/s10792-024-02983-4.
To review the risk of endophthalmitis in same-day bilateral anti-VEGF injections.
We searched 12 literature databases for studies on the risk of endophthalmitis after same-day bilateral intravitreal anti-VEGF injections. Data extraction was made independently by two authors and discussed afterward until reaching consensus.
Seventeen studies were included with a total of 138,478 intravitreal anti-VEGF injections (69,239 bilateral injections sessions) given in at least 7579 patients. In total, 33 cases of endophthalmitis had occurred, and no cases were bilateral. The incidence of endophthalmitis ranged from 0 to 0.53% per intravitreal injection across studies.
We suggest that clinicians can consider same-day treatment of both eyes of patients in need of bilateral intravitreal anti-VEGF injection therapy, but larger studies are needed to quantify the exact risk of endophthalmitis.
回顾同日双侧抗血管内皮生长因子（anti-VEGF）注射后发生眼内炎的风险。
我们检索了12个文献数据库，以查找关于同日双侧玻璃体内抗VEGF注射后眼内炎风险的研究。由两位作者独立进行数据提取，之后进行讨论直至达成共识。
纳入了17项研究，至少7579例患者共接受了138,478次玻璃体内抗VEGF注射（69,239次双侧注射疗程）。总共发生了33例眼内炎病例，无双侧病例。各研究中玻璃体内注射的眼内炎发生率为0至0.53%。
我们建议临床医生可以考虑对需要双侧玻璃体内抗VEGF注射治疗的患者同日进行双眼治疗，但需要更大规模的研究来量化眼内炎的确切风险。
